VIA
ALDX icon

Vantage Investment Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Vantage Investment Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2,000
Closed -$8K – 838
2016
Q1 		$8K Hold
2,000
– – ﹤0.01% 551
2015
Q4 		$14K Hold
2,000
– – 0.01% 442
2015
Q3 		$12K Hold
2,000
– – 0.01% 456
2015
Q2 		$16K Buy
+2,000
New +$17.2K 0.01% 408

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vantage Investment Advisors's ALDX Position: Q2 2016 in Review

Vantage Investment Advisors sold out of Aldeyra Therapeutics (ALDX) in Q2 2016, closing a stake of 2,000 shares — an estimated $8K sold.

Vantage Investment Advisors first reported a position in ALDX in Q2 2015 and held it in 4 quarters. The position peaked at $16K in Q2 2015. 25 funds tracked by Wall St. Rank hold ALDX as of Q2 2016.

  • Vantage Investment Advisors reported no remaining Aldeyra Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Vantage Investment Advisors sold 2,000 Aldeyra Therapeutics shares in Q2 2016, an estimated $8K.
  • Vantage Investment Advisors first reported a position in Aldeyra Therapeutics in Q2 2015 and held it in 4 quarters.
  • Vantage Investment Advisors's Aldeyra Therapeutics position peaked at $16K in Q2 2015.
  • 25 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2016.

Based on Vantage Investment Advisors's 13F filing for Q2 2016, filed 12 Aug 2016.